(Yicai Global) Nov. 20 -- Amoy Diagnostics has gotten the green light to sell the country's first next-generation sequencing gene testing products in China.
Amoy, also known as AmoyDx, received the approval from the National Drug Administration for its human 10-gene mutation combined detection kit, which is used for diagnosing non-small-cell lung cancer and colorectal cancer, the Xiamen-based firm said in a statement today.
The firm's [SHE: 300685] share price rose more than 2 percent to CNY50.71 at 1.30 p.m. yesterday. The stock has fallen slightly today to close at CNY49.98.
Editor: Emmi Laine